HTPEP AT01
Alternative Names: HTPEP-AT01Latest Information Update: 07 Feb 2025
At a glance
- Originator Chengdu Huitai Biomedicine Co
- Class Antifibrotics; Antineoplastics; Monoclonal antibodies; Peptides
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis; Solid tumours
Most Recent Events
- 19 Dec 2024 Preclinical trials in Fibrosis in China (IV), prior to December 2024 (Huitai Biomedicine pipeline, December 2024)
- 19 Dec 2024 Preclinical trials in Solid tumours in China (IV), prior to December 2024 (Huitai Biomedicine pipeline, December 2024)
- 19 Dec 2024 Pharmacodynamics data from preclinical trials in Solid tumours released by Chengdu Huitai Biomedicine